# A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

> **NCT04917809** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 20 (actual)

## Conditions studied

- Bladder Cancer
- Recurrent Bladder Cancer
- FGFR3 Gene Mutation

## Interventions

- **DRUG:** Erdafitinib

## Key facts

- **NCT ID:** NCT04917809
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-17
- **Primary completion:** 2026-08
- **Final completion:** 2026-08
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04917809

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04917809, "A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04917809. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*